Effects of Targeted Anticancer Medicines on Post-Cell Removal Surface Morphology of Cancer Cells Cultivated on 3-Aminopropyltriethoxysilane SurfaceChung-Ping Hsu1,2, You-Lin Wu3*, Wan-Yun Lee3, Li-Wen Li1 and Jing-Jenn Lin4
- *Corresponding Author:
- You-Lin Wu
Department of Electrical Engineering, National Chi Nan University
301 University Rd., Puli, Nanto, Taiwan, 54561
Tel: +886-49-2910960 (X-4805)
E-mail: [email protected]
Received date: April 26, 2014; Accepted date: May 28, 2014; Published date: May 30, 2014
Citation: Hsu CP, Wu YL, Lee WY, Li LW, Lin JJ (2014) Effects of Targeted Anticancer Medicines on Post-Cell Removal Surface Morphology of Cancer Cells Cultivated on 3-Aminopropyltriethoxysilane Surface. Med chem S1: 007. doi: 10.4172/2161-0444.S1-007
Copyright: © 2014 Hsu CP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A post-cell-removal surface morphology (PCRSM) profiling technique was used to identify the effects of targeted anticancer medicines on cancer cells. Living non-small lung cancer cells, A549 and H1299, were cultivated on a 3-aminopropyltriethoxysilane (γ-APTES) coated silicon wafer surface with and without targeted anticancer medicine added in the culture medium. Atomic force microscopy (AFM) was used to examine the surface morphology profile on the γ-APTES wafer surface after removing the cells. Two different targeted anticancer medicines, epidermal growth factor receptor (EGFR)-inhibitor Iressa (gefitinib) and protein kinase c (PKC)-inhibitor Staurosporine were examined. Our experimental results show that only the cancer cells treated with Staurosporine can have the PCRSM profiles resemble to those of normal cells, whereas those treated with Iressa reserve the PCRSM profiles of the pre-medicine treated cancer cells. This observation indicates that the PCRSM technique is able to detect the cell-traction force difference caused by EGFR-inhibitor and PKC-inhibitor, respectively and Staurosporine is more effective than Iressa in deactivating the cell-substrate interaction of the cancer cells.